APP Pharmaceuticals, a company that develops, makes, and markets anesthetics and other injectable drugs. Specializing in generics, APP's critical care products segment includes market-leading general anesthetic Diprivan and blood thinner Heparin. Other product segments focus on injectable oncology treatments and drugs that fight ear, heart, respiratory tract, skin, and sinus infections. APP markets through a direct sales force and often sells through group purchasing organizations to customers that include hospitals, long-term care facilities, and clinics in North America. APP Pharmaceuticals, LLC company is a subsidiary of German medical firm Fresenius.

Cancer is the only target of Onyvax. The development-stage biotech aims to come up with novel immunotherapies to treat advanced prostate and other forms of cancer. Onyvax's therapeutic cancer vaccines combine inactivated cell lines that create immune responses to tumor targets. The firm has several products in clinical trials, including lead candidate Onyvax-P, a cell vaccine that could treat hormone-resistant prostate cancer. While most of the company's candidates target specific types of cancer, its Onyvax-105 uses human monoclonal antibodies to attack the CD55 molecule, giving the therapy potential for treating many types of cancer.

For biotechnology and pharmaceutical companies whose next big breakthrough is stuck in the test tube, Oxford Therapeutics Consulting could have the answer. The product development consulting firm offers strategic planning and product management for biotechs and pharmas that are short on staff and experience in bringing a new product through the lengthy development pipeline. Oxford Therapeutics' team of consultants work primarily with smaller companies on products such as anticancer agents, antibacterial and antiviral compounds, and therapeutic vaccines.

Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts. Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system. The company offers Protein A products, which are used in the production and purification of therapeutic monoclonal antibodies. Repligen also licenses its patent covering the use of CTLA4-Ig, a regulator of the activity of the immune system, and receives royalties from Bristol-Myers Squibb based on their U.S. Sales of Orencia. The company's development stage products include RG1068, human secretin for improved MRI of the pancreas; RG2417, uridine for bipolar depression; HDAC inhibitors for Friedreich's ataxia; and RG-SMA for spinal muscular atrophy. The company sells its Protein A products primarily through value-added resellers, as well as through distributors internationally.

Sanofi Pasteur helps you guard against getting sick in the first place. The company is the US vaccines division of French drugmaker Sanofi-Aventis. It makes vaccines that protect against such infectious diseases as influenza, polio, and meningitis. Some of its top sellers are flu vaccines, childhood combination vaccines, and adult booster shots. It also makes travelers' vaccines that keep globetrotters safe from typhoid, cholera, yellow fever, and the like. Projects in development include improved vaccines for influenza, preventative vaccines for HIV and dengue fever, and therapeutic vaccines for cancer.

Cobra Biomanufacturing offers contract research and manufacturing services to the biopharmaceutical industry. It develops genetic research supplies for use in preclinical research and early clinical trial stages. The company helps its global clients navigate through regulatory requirements while designing and manufacturing novel proteins, viruses, and other cellular products for use in drug development and manufacturing processes. Clients use Cobra Biomanufacturing's products and technologies to develop gene-based disease therapies and vaccine products.

Marligen Biosciences is where researchers go again and again for testing products and services. The company makes nucleic acid purification systems, genetic analysis assays, and other genomics research supplies. Its nucleic acid purification systems include rapid plasma purification systems which are used for isolation DNA so it can mapped, cloned, amplified, labeled, and sequenced. Its genetic analysis assays are sold under the Signet brand name and can screen for certain classes of DNA or be tailored to the researchers needs. Marlingen was acquired by another genetic services provider, OriGene, in 2009.

Santhera Pharmaceuticals Holding AG (Santhera) is a Swiss company focused on discovery, development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases. CATENA is Santhera’s first product approved in Canada for symptomatic treatment of Friedreich's ataxia. Santhera has five clinical-stage development programs, three of which investigate its core compound, SNT-MC17/idebenon, in the treatment of Friedreich’s ataxia, Duchenne muscular dystrophy and Leber’s hereditary optic neuropathy. Another clinical program investigates JP-1730/fipamezole in the treatment of dyskinesia in Parkinson’s disease. The fifth program concerns congenital muscular dystrophies. It operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, engaged in research and development of pharmaceuticals, Santhera Pharmaceuticals (Canada), Inc., active in marketing and sales of pharmaceuticals, and Santhera Pharmaceuticals (USA), Inc.

BTG plc company acquires patent rights to new technologies and licenses them to manufacturers around the globe. With a focus on biopharmaceuticals and medical products, BTG reviews prospective technologies developed by research institutions, universities, and companies around the globe. In addition, BTG helps raise venture capital for start-up businesses and creates ventures (often through partnerships) to exploit new technologies. Originally set up by the British government to protect and patent British inventions, BTG has helped bring to market such famous inventions as the hovercraft and magnetic resonance imaging (MRI).

Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.